Alnylam Pharmaceuticals (ALNY) News Today $313.47 +4.76 (+1.54%) As of 01:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ALNY Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Alnylam Announces Promotion of Pushkal Garg to Chief Research and Development OfficerJune 18 at 10:05 AM | businesswire.comAssenagon Asset Management S.A. Reduces Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Assenagon Asset Management S.A. cut its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 67.8% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,405 shares of the biopharmaceutical company's stock afterJune 18 at 3:39 AM | marketbeat.comNorthCrest Asset Manangement LLC Makes New Investment in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)NorthCrest Asset Manangement LLC purchased a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,196 shares of the biopharmacJune 16 at 4:06 AM | marketbeat.comRBC Capital Remains a Buy on Alnylam Pharma (ALNY)June 15 at 1:39 AM | theglobeandmail.comAlnylam Pharmaceuticals' SWOT analysis: stock poised for growth in expanding ATTR-CM marketJune 14, 2025 | investing.comJPMorgan Chase & Co. Issues Positive Forecast for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock PriceJune 14, 2025 | americanbankingnews.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Downgraded by Wall Street Zen to HoldWall Street Zen cut Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Saturday.June 14, 2025 | marketbeat.comTobam Sells 8,418 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Tobam cut its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 71.4% during the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 3,366 shares of the biopharmaceutical company's stock after sellingJune 13, 2025 | marketbeat.comWhat 18 Analyst Ratings Have To Say About Alnylam PharmaceuticalsJune 12, 2025 | benzinga.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Given New $338.00 Price Target at JPMorgan Chase & Co.JPMorgan Chase & Co. increased their price objective on shares of Alnylam Pharmaceuticals from $330.00 to $338.00 and gave the company an "overweight" rating in a research report on Thursday.June 12, 2025 | marketbeat.comThe European Commission Approves Alnylam’s AMVUTTRAJune 11, 2025 | msn.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stake Boosted by Bannerman Wealth Management Group LLCBannerman Wealth Management Group LLC grew its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 96.2% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,729 sharJune 11, 2025 | marketbeat.comHandelsbanken Fonder AB Purchases 62,337 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Handelsbanken Fonder AB increased its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 114.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 116,683 shares of the biopharmacJune 11, 2025 | marketbeat.com2,483 Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Acquired by Accurate Wealth Management LLCAccurate Wealth Management LLC bought a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 2,483 shares of the biopJune 11, 2025 | marketbeat.comEC approves Alnylam’s vutrisiran for ATTR-CM treatmentJune 10, 2025 | msn.comSG Americas Securities LLC Has $35.90 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)SG Americas Securities LLC boosted its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 7,876.0% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 132,960 shares of the biopharmaceutical compJune 10, 2025 | marketbeat.comPallas Capital Advisors LLC Acquires 3,227 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Pallas Capital Advisors LLC lifted its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 94.7% in the first quarter, according to its most recent filing with the SEC. The firm owned 6,635 shares of the biopharmaceutical company's stock after acquiring an additionalJune 10, 2025 | marketbeat.comAlnylam Gets Expanded European OK for Amvuttra in ATTR-CMJune 9, 2025 | marketwatch.comAlnylam Pharmaceuticals Secures European Approval for AMVUTTRA in Treating ATTR-CM | ALNY stock newsJune 9, 2025 | gurufocus.comAlnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with CardiomyopathyJune 9, 2025 | businesswire.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Gateway Investment Advisers LLCGateway Investment Advisers LLC lessened its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 11.4% in the first quarter, according to its most recent filing with the SEC. The fund owned 6,540 shares of the biopharmaceutical company's stock after selling 843 shares duJune 9, 2025 | marketbeat.comTB Alternative Assets Ltd. Buys New Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)TB Alternative Assets Ltd. bought a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 9,168 shares of the biopharmaceutical company's stock,June 8, 2025 | marketbeat.comMerit Financial Group LLC Grows Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Merit Financial Group LLC increased its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 113.0% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,314 shares of the biopharmacJune 7, 2025 | marketbeat.comRegeneron Pharmaceuticals, Inc. (REGN): A Bull Case TheoryJune 6, 2025 | msn.comWhat is HC Wainwright's Estimate for ALNY Q2 Earnings?Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) - Analysts at HC Wainwright raised their Q2 2025 earnings per share estimates for shares of Alnylam Pharmaceuticals in a research note issued to investors on Monday, June 2nd. HC Wainwright analyst P. Trucchio now expects that the biopharmJune 5, 2025 | marketbeat.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Sets New 12-Month High - Still a Buy?Alnylam Pharmaceuticals (NASDAQ:ALNY) Hits New 12-Month High - Time to Buy?June 5, 2025 | marketbeat.comWealth Enhancement Advisory Services LLC Raises Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Wealth Enhancement Advisory Services LLC boosted its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 94.7% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 12,566 shares of the biopharmaceutiJune 5, 2025 | marketbeat.comInsider Selling: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CEO Sells 19,297 Shares of StockAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) CEO Yvonne Greenstreet sold 19,297 shares of the firm's stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $306.00, for a total value of $5,904,882.00. Following the completion of the sale, the chief executive officer now directly owns 48,948 shares of the company's stock, valued at approximately $14,978,088. The trade was a 28.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.June 4, 2025 | marketbeat.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CEO Yvonne Greenstreet Sells 31,640 SharesAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) CEO Yvonne Greenstreet sold 31,640 shares of the stock in a transaction dated Friday, May 30th. The shares were sold at an average price of $304.39, for a total transaction of $9,630,899.60. Following the completion of the sale, the chief executive officer now owns 48,948 shares of the company's stock, valued at approximately $14,899,281.72. This trade represents a 39.26% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.June 4, 2025 | marketbeat.comInsider Selling: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CEO Sells 19,297 Shares of StockJune 4, 2025 | insidertrades.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Purchased by Rhumbline AdvisersRhumbline Advisers boosted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 1.0% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 181,463 shares of the biopharmaceutical company's stock after acquiring an additional 1,88June 4, 2025 | marketbeat.comGAMMA Investing LLC Has $44.91 Million Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)GAMMA Investing LLC lifted its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 30,759.4% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 166,332 shares of the biopharmaceutiJune 4, 2025 | marketbeat.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Consensus Rating of "Moderate Buy" from AnalystsShares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) have been given a consensus rating of "Moderate Buy" by the twenty-six research firms that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, foJune 4, 2025 | marketbeat.comAlnylam Pharmaceuticals (ALNY) Price Target Raised to $500 by H.C. WainwrightJune 3, 2025 | insidermonkey.comSummit Global Investments Invests $849,000 in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Summit Global Investments bought a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 3,145 shares of the biopharmaceutical company's stock, valJune 1, 2025 | marketbeat.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Mackenzie Financial CorpMackenzie Financial Corp cut its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 55.0% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 8,859 shares of the biopharmaceutical company's stock after selling 10,8June 1, 2025 | marketbeat.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Sets New 12-Month High - Should You Buy?Alnylam Pharmaceuticals (NASDAQ:ALNY) Reaches New 52-Week High - Should You Buy?May 31, 2025 | marketbeat.comGTS Securities LLC Trims Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)GTS Securities LLC cut its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 83.2% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,163 shares of the biopharmMay 31, 2025 | marketbeat.com42,544 Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Bought by Lansforsakringar Fondforvaltning AB publLansforsakringar Fondforvaltning AB publ purchased a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 42,544 sharesMay 30, 2025 | marketbeat.comSiemens Fonds Invest GmbH Boosts Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Siemens Fonds Invest GmbH raised its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 137.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 3,245 shares of the biopharmaceutical company's stock after purchasinMay 30, 2025 | marketbeat.comUniversal Beteiligungs und Servicegesellschaft mbH Invests $29.26 Million in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 124,360 shares of the biopharmacMay 30, 2025 | marketbeat.comIntellia's Stock Drops Following Adverse Event in Nex-Z TrialMay 29, 2025 | marketwatch.comWhy Alnylam Could Outperform In The Transthyretin Amyloidosis With Cardiomyopathy FieldMay 29, 2025 | seekingalpha.comCalifornia State Teachers Retirement System Acquires 5,037 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)California State Teachers Retirement System lifted its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 2.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 196,362 shares of the biopharmMay 29, 2025 | marketbeat.comBannerman Wealth Management Group LLC Acquires Shares of 1,391 Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Bannerman Wealth Management Group LLC acquired a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 1,391 shares of the biopharmaceuticalMay 29, 2025 | marketbeat.comVoloridge Investment Management LLC Has $3.95 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Voloridge Investment Management LLC cut its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 91.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 16,776 shares of the biopharmaceutiMay 29, 2025 | marketbeat.comAlnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare ConferenceMay 29, 2025 | finance.yahoo.comAre Brighter Days Ahead for This Fidelity Health Care Fund?May 28, 2025 | msn.comBiogen partners with John Maraganore’s new RNAi startupMay 27, 2025 | bizjournals.comGF Fund Management CO. LTD. Takes $637,000 Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)GF Fund Management CO. LTD. bought a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 2,708 shares of the biopharmaceutMay 27, 2025 | marketbeat.com Get Alnylam Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter. Email Address ALNY Media Mentions By Week ALNY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALNY News Sentiment▼1.080.56▲Average Medical News Sentiment ALNY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALNY Articles This Week▼1215▲ALNY Articles Average Week Get Alnylam Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Amgen News Gilead Sciences News Vertex Pharmaceuticals News Regeneron Pharmaceuticals News Biogen News Incyte News United Therapeutics News Neurocrine Biosciences News Exelixis News BioMarin Pharmaceutical News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALNY) was last updated on 6/18/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe stealth altcoin the financial world is underestimatingWhile everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s End Game Is Going Live -- And It Could Make You a FortuneThe media and the so-called experts have laughed at Elon Musk his entire career. CBS called PayPal “one of ...The Oxford Club | SponsoredSorry about the swear wordWhat a huge few months for Bitcoin. First, Bitcoin hit $100,000… Then, Donald Trump pledged to create an...Manward Press | SponsoredThe Dollar Reset Nobody’s Talking AboutCould this man take down the financial system? In March, the Senate granted sweeping powers to a Harvard ec...Stansberry Research | SponsoredBREAKING: Trump vs. Elon Feud Threatens Your Retirement – Protect Yourself NOW"This isn't just a war of words. This is a financial time bomb. The escalating battle between Donald Trump a...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alnylam Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alnylam Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ALNY Stock Free ALNY Stock Alerts